Pathobiology 2008;75:156–170

Comparative Efficacy of Two Microdoses of a Potentized Homeopathic Drug, Arsenicum Album, to Ameliorate Toxicity Induced by Repeated Sublethal Injections of Arsenic Trioxide in Mice

Banerjee P.a · Bhattacharyya S.S.a · Pathak S.a · Naoual B.b · Belon P.b · Khuda-Bukhsh A.R.a
aCytogenetics and Molecular Biology Laboratory, Department of Zoology, University of Kalyani, Kalyani, India; bBoiron Lab, Sainte-Foy-lès-Lyon, France
email Corresponding Author

 goto top of outline Key Words

  • Arsenic toxicity
  • Mice
  • Biomarkers
  • Homeopathy
  • Matrix metalloproteinase

 goto top of outline Abstract

Objectives: To evaluate the efficacy of 2 potentized homeopathic remedies of Arsenicum Album (Ars Alb) – 6C and 30C – in combating chronic arsenic toxicity induced by repeated sublethal injections in mice (Mus musculus). Methods: Mice were randomized and divided into sets: (1) normal (control 1); (2) normal + succussed alcohol (control 2); (3) As2O3 (0.016%) injected at 1 ml/100 g body weight every 7 days (treated); (4) As2O3 injected + succussed alcohol (positive control); (5) As2O3 injected + Ars Alb 6C (drug-fed); (6) As2O3 injected + Ars Alb 30C (drug-fed). Cytogenetical endpoints like chromosome aberrations, micronuclei, mitotic index, sperm head abnormality and biochemical protocols like acid and alkaline phosphatases, aspartate and alanine aminotransferases, reduced glutathione, lipid peroxidation, catalase and succinate dehydrogenase were studied at 30, 60, 90 and 120 days. Results: Compared to controls, chromosome aberrations, micronuclei, sperm head abnormality frequencies and activities of acid and alkaline phosphatases, aspartate and alanine aminotransferases and lipid peroxidation were reduced in both drug-fed series, while mitotic index and activities of glutathione, catalase and succinate dehydrogenase were increased. Ars Alb 30C showed marginally better efficacy than Ars Alb 6C. Conclusion: Both remedies indicated potentials of use against arsenic intoxication.

Copyright © 2008 S. Karger AG, Basel

 goto top of outline References
  1. Rahman M, Tondel M, Ahmad SA: Hypertension and arsenic exposure in Bangladesh. Hypertension 1999;33:74–78.
  2. Engel RR, Smith AH: Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States. Arch Environ Health 1994;49:418–427.
  3. Wu MM, Kuo TL, Hwang YH, Chen CJ: Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 1989;130:1123–1132.
  4. Hu H: Exposure to metals. Prim Care 2000;27:983–996.
  5. Chen CJ, Wang CJ: Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 1990;50:5470–5474.
  6. International Programme on Chemical Safety: Inorganic Arsenic Compounds Other than Arsine. Health and Safety Guide No. 70. Geneva, World Health Organization, 1992.
  7. International Programme on Chemical Safety: Environmental Health Criteria Document 224: Arsenic and Arsenic Compounds. Geneva, World Health Organization, 2001.
  8. International Agency for Research on Cancer: Summaries and Evaluations: Arsenic and Arsenic Compounds. Lyon, International Agency for Research on Cancer, 1987.
  9. Department for Environment Food and Rural Affairs, Environment Agency: Contaminants in Soil: Collation of Toxicological Data and Intake Values for Humans. Arsenic. Bristol, Environment Agency, 2002.
  10. Tchounwou PB, Wilson BA, Ishaque A: Important considerations in the development of public health advisories for arsenic and arsenic containing compounds in drinking water. Rev Environ Health 1999;14:1–19.

    External Resources

  11. National Academy of Sciences: Arsenic. Washington, National Academy of Sciences, 1977.
  12. Overall evaluation of carcinogenicity: an update of IARC monographs. IARC Monogr Eval Carcinog Risks Hum 1989;47:1–42.

    External Resources

  13. Mitra K, Kundu SN, Khuda-Bukhsh AR: Efficacy of a potentized homeopathic drug (arsenicum album-30) in reducing toxic effects produced by arsenic trioxide in mice: I. On the rate of accumulation of arsenic in certain vital organs. Complement Ther Med 1998;6:178–184.

    External Resources

  14. Mitra K, Kundu SN, Khuda-Bukhsh AR: Efficacy of a potentized homeopathic drug (arsenicum album-30) in reducing toxic effects produced by arsenic trioxide in mice: II. On alterations of body weight, tissue weight and total protein. Complement Ther Med 1999;7:24–34.
  15. Kundu SN, Mitra K, Khuda-Bukhsh AR: Efficacy of a potentized homeopathic drug (arsenicum album-30) in reducing cytotoxic effects produced by arsenic trioxide in mice: III. Enzymatic changes and recovery of tissue damage in liver. Complement Ther Med 2000;8:76–81.
  16. Kundu SN, Mitra K, Khuda-Bukhsh AR: Efficacy of a potentized homeopathic drug (arsenicum album-30) in reducing cytotoxic effects produced by arsenic trioxide in mice: IV. Pathological changes, protein profiles and content of DNA and RNA. Complement Ther Med 2000;8:157–175.
  17. Datta S, Mallick P, Khuda-Bukhsh AR: Efficacy of a potentized homeopathic drug (arsenicum album-30) in reducing genotoxic effects produced by arsenic trioxide in mice: comparative studies of pre-, post- and combined pre- and post-oral administration and comparative efficacy of two microdoses. Complement Ther Med 1999;7:62–75.
  18. Mallick P, Chakrabarti Mallick J, Guha B, Khuda-Bukhsh AR: Ameliorating effect of microdoses of a potentized homeopathic drug, arsenicum album, on arsenic induced toxicity in mice. BMC Complement Altern Med 2003;3:1–19.
  19. Pathak S, Das JK, Biswas SJ, Khuda-Bukhsh AR: Protective potentials of a potentized homeopathic drug, Lycopodium-30, in ameliorating azo dye induced hepatocarcinogenesis in mice. Mol Cell Biochem 2006;258:121–131.

    External Resources

  20. Biswas SJ, Pathak S, Khuda-Bukhsh AR: Assessment of the genotoxic and cytotoxic potential of an antiepileptic drug phenobarbital, in mice: a time course study. Mutat Res 2004;563:1–11.
  21. Pathak S, Bhattacharjee N, Das JK, Choudhury SC, Karmakar SR, Banerjee P, Paul S, Banerjee A, Khuda-Bukhsh AR: Supportive evidence for the anticancerous potential of alternative medicine against hepatocarcinogenesis in mice. Forsch Komplement Med (2006) 2007;14:148–156.
  22. Billings PC, Habres JM, Liao DC, Tuttle SW: Human fibroblasts contain a proteolytic activity, which is inhibited by the Bowman-Birk protease inhibitor. Cancer Res 1991;51:5539–5543.
  23. Locke J: The determination of eight elements in human liver tissue by flame atomic absorption spectrometry in sulphuric acid solution. Anal Chem Acta 1979;104:225–231.
  24. Nurenberg WH: Voltametric trace analysis in ecological chemistry of toxic metals. Pure Appl Chem 1982;54:853–878.

    External Resources

  25. Fisher RA, Yates F: Statistical Tables for Biological, Agricultural and Medical Research. Edinburgh, Oliver and Boyd, 1963.
  26. Pi JB, Yamauchi H, Kumagai Y: Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect2002;110:331–336.
  27. Flora SJS: Arsenic-induced oxidative stress and its reversibility following combined administration of N-acetylcysteine and meso 2,3-dimercaptosuccinic acid in rats. Clin Exp Pharmacol Physiol 1999;26:865–869.
  28. Maiti S, Chatterjee AK: Effects on levels of glutathione and some related enzymes in tissues after an acute arsenic exposure in rats and their relationship to dietary protein deficiency. Arch Toxicol 2001;75:531–537.
  29. Guha Mazumder DN, Das Gupta J, Santra A, Pal A, Ghose A, Sarkar S, Chattopadhaya N, Chakraborti D: Non-cancer effects of chronic arsenicosis with special reference to liver damage; in Aberthy CO, Calderon RL, Chappel WR (eds): Arsenic: Exposure and Health Effects. London, Chapman and Hall, 1997, pp 113–123.
  30. Sternlicht MD, Werb Z: How matrix metalloproteases regulate cell behaviour. Annu Rev Cell Dev Biol 2001;17:463–516.
  31. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327–336.
  32. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling (review). Trends Genet 1990;6:121–125.
  33. Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145–2154.
  34. Lee AY, Akers KT, Collier M, Li L, Eisen AZ, Seltzer JL: Intracellular activation of gelatinase A (72-kDa type IV collagenase) by normal fibroblasts. Proc Natl Acad Sci USA 1997;94:4424–4429.
  35. Seltzer JL, Lee AY, Akers KT, Sudbeck B, Southon EA, Wayner EA, Eisen AZ: Activation of 72-kDa type IV collagenase/gelatinase by normal fibroblasts in collagen lattices is mediated by integrin receptors but is not related to lattice contraction. Exp Cell Res 1994;213:365–374.
  36. Birkedal-Hansen H: Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995;7:728–735.
  37. Ray JM, Stetler-Stevenson WG: The role of matrix metalloproteases and their inhibitors in tissue invasion, metastasis and angiogenesis. Eur Respir J 1994;7:2062–2072.
  38. Wang Z, Juttermann R, Soloway PD: TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 2000;275:26411–26415.
  39. Khuda-Bukhsh AR: Potentized homeopathic drugs act through regulation of gene expression: a hypothesis to explain their mechanism and pathways of action in vivo. Complement Ther Med 1997;5:43–46.

    External Resources

  40. Khuda-Bukhsh AR: Towards understanding molecular mechanisms of action of homeopathic drugs: an overview. Mol Cell Biochem 2003;253:339–345.
  41. Khuda-Bukhsh AR: Laboratory research in homeopathy: pro. Integr Cancer Ther 2006;5:320–332.

 goto top of outline Author Contacts

Anisur R. Khuda-Bukhsh
Department of Zoology, University of Kalyani
Kalyani, West Bengal 741235 (India)
Tel. +91 33 2582 8768, Fax +91 33 2582 8282, E-Mail

 goto top of outline Article Information

Received: July 17, 2007
Accepted after revision: November 13, 2007
Published online: June 10, 2008
Number of Print Pages : 15
Number of Figures : 12, Number of Tables : 8, Number of References : 41

 goto top of outline Publication Details

Pathobiology (Pathobiology - Exploring the basis of disease)

Vol. 75, No. 3, Year 2008 (Cover Date: June 2008)

Journal Editor: Borisch B. (Geneva), Yasui W. (Hiroshima)
ISSN: 1015–2008 (Print), eISSN: 1423–0291 (Online)

For additional information:

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.